Taro Pharmaceutical Indus Q1 EPS $0.27 Down From $0.37 YoY, Sales $158.89M Up From $156.66M YoY
Portfolio Pulse from Benzinga Newsdesk
Taro Pharmaceutical Indus (NYSE:TARO) reported Q1 earnings of $0.27 per share, a 27.03% decrease YoY. However, the company's sales increased by 1.42% to $158.89 million.
July 27, 2023 | 6:40 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Taro Pharmaceutical's Q1 earnings decreased by 27.03% YoY, while sales increased by 1.42%.
The decrease in earnings per share indicates a decline in profitability, which could negatively impact the stock price. However, the increase in sales could offset this to some extent.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100